Criteria Caixa’s AbbVie ABBV Stock Holding History

Criteria Caixa’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,000	Closed	-$539K	–	38
2023 Q2	$539K	Buy	+4,000	New	+$587K	0.06%	41
2021 Q4	–	Sell	-12,000	Closed	-$1.29M	–	42
2021 Q3	$1.29M	Buy	+12,000	New	+$1.37M	0.18%	35
2021 Q2	–	Sell	-10,000	Closed	-$1.08M	–	41
2021 Q1	$1.08M	Buy	10,000 +4,500	+82%	+$481K	0.17%	27
2020 Q4	$589K	Sell	5,500 -2,000	-27%	-$192K	0.11%	37
2020 Q3	$657K	Buy	+7,500	New	+$706K	0.15%	30

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Criteria Caixa's ABBV Position: Q4 2025 in Review

Criteria Caixa sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 495,162 shares — an estimated $115M sold.

Criteria Caixa first reported a position in ABBV in Q4 2019 and held it in 23 quarters. The position peaked at $115M in Q3 2025. 4,147 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Criteria Caixa reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
Criteria Caixa sold 495,162 AbbVie shares in Q4 2025, an estimated $115M.
Criteria Caixa first reported a position in AbbVie in Q4 2019 and held it in 23 quarters.
Criteria Caixa's AbbVie position peaked at $115M in Q3 2025.
4,147 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Criteria Caixa's 13F filing for Q4 2025, filed 17 Feb 2026.